Repros Therapeutics Inc. (NASDAQ:RPRX) traded down 6.5% during trading on Wednesday . The stock traded as low as $0.65 and last traded at $0.65. 1,409,880 shares traded hands during trading, an increase of 32% from the average session volume of 1,071,400 shares. The stock had previously closed at $0.69.
Separately, Laidlaw lowered Repros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, July 21st.
The firm’s market cap is $24.26 million. The company’s 50 day moving average is $0.36 and its 200 day moving average is $0.56.
Repros Therapeutics (NASDAQ:RPRX) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.14. The business had revenue of $0.01 million during the quarter. Repros Therapeutics had a negative net margin of 56,062.07% and a negative return on equity of 412.64%. Equities research analysts forecast that Repros Therapeutics Inc. will post ($1.07) earnings per share for the current year.
An institutional investor recently raised its position in Repros Therapeutics stock. Renaissance Technologies LLC boosted its holdings in Repros Therapeutics Inc. (NASDAQ:RPRX) by 1.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 727,113 shares of the biotechnology company’s stock after acquiring an additional 10,700 shares during the quarter. Renaissance Technologies LLC owned about 2.73% of Repros Therapeutics worth $873,000 as of its most recent SEC filing. 14.52% of the stock is owned by institutional investors and hedge funds.
Repros Therapeutics Company Profile
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
What are top analysts saying about Repros Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Repros Therapeutics Inc. and related companies.